R P Mischak

737 total citations
12 papers, 605 citations indexed

About

R P Mischak is a scholar working on Immunology, Biotechnology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, R P Mischak has authored 12 papers receiving a total of 605 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Immunology, 5 papers in Biotechnology and 4 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in R P Mischak's work include Toxin Mechanisms and Immunotoxins (7 papers), Transgenic Plants and Applications (5 papers) and Monoclonal and Polyclonal Antibodies Research (4 papers). R P Mischak is often cited by papers focused on Toxin Mechanisms and Immunotoxins (7 papers), Transgenic Plants and Applications (5 papers) and Monoclonal and Polyclonal Antibodies Research (4 papers). R P Mischak collaborates with scholars based in United States and France. R P Mischak's co-authors include Lynn E. S̄pitler, Beatrice Langton-Webster, Laura K. Shawver, Tiffany Chan, N A Brophy, Archie Khentigan, Nancy Wedel, W. Scott Harkonen, L.L. Miller and Maguy Del Rio and has published in prestigious journals such as Annals of the New York Academy of Sciences, Antimicrobial Agents and Chemotherapy and Infection and Immunity.

In The Last Decade

R P Mischak

12 papers receiving 563 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
R P Mischak United States 9 253 237 229 209 132 12 605
Y Fukushi Japan 10 285 1.1× 325 1.4× 75 0.3× 716 3.4× 48 0.4× 24 877
Gretchen N. Schwartz United States 15 237 0.9× 91 0.4× 172 0.8× 210 1.0× 31 0.2× 33 616
Gerald R. Thrush United States 8 242 1.0× 65 0.3× 201 0.9× 137 0.7× 62 0.5× 11 474
Sabine Imhof-Jung Switzerland 9 204 0.8× 392 1.7× 177 0.8× 329 1.6× 78 0.6× 13 654
Raúl A. Ruggiero Argentina 14 207 0.8× 46 0.2× 260 1.1× 137 0.7× 44 0.3× 38 552
L Chaplin United Kingdom 11 132 0.5× 280 1.2× 79 0.3× 238 1.1× 16 0.1× 15 517
Birgitta Clinchy Sweden 10 193 0.8× 112 0.5× 82 0.4× 131 0.6× 61 0.5× 21 377
Г. И. Дейчман Russia 14 160 0.6× 50 0.2× 216 0.9× 214 1.0× 63 0.5× 41 554
Kazuko Tsuneoka Japan 11 176 0.7× 96 0.4× 93 0.4× 132 0.6× 19 0.1× 27 389
H von Boehmer Switzerland 11 644 2.5× 177 0.7× 108 0.5× 172 0.8× 14 0.1× 15 811

Countries citing papers authored by R P Mischak

Since Specialization
Citations

This map shows the geographic impact of R P Mischak's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by R P Mischak with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites R P Mischak more than expected).

Fields of papers citing papers by R P Mischak

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by R P Mischak. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by R P Mischak. The network helps show where R P Mischak may publish in the future.

Co-authorship network of co-authors of R P Mischak

This figure shows the co-authorship network connecting the top 25 collaborators of R P Mischak. A scholar is included among the top collaborators of R P Mischak based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with R P Mischak. R P Mischak is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

12 of 12 papers shown
1.
Yang, Lichuan, Shuei Sugama, R P Mischak, et al.. (2004). A novel systemically active caspase inhibitor attenuates the toxicities of MPTP, malonate, and 3NP in vivo. Neurobiology of Disease. 17(2). 250–259. 67 indexed citations
2.
Clemens, L. Edward, et al.. (1998). Pharmacokinetics and Biological Actions of Subcutaneously Administered Human Brain Natriuretic Peptide. Journal of Pharmacology and Experimental Therapeutics. 287(1). 67–71. 13 indexed citations
3.
Langton-Webster, Beatrice, et al.. (1991). A monoclonal antibody against the c-erbB-2 protein enhances the cytotoxicity of cis-diamminedichloroplatinum against human breast and ovarian tumor cell lines.. PubMed. 51(17). 4575–80. 200 indexed citations
4.
Mischak, R P, et al.. (1990). The effects of cyclophosphamide on the toxicity and immunogenicity of ricin A chain immunotoxin in rats.. PubMed. 2(3). 179–84. 4 indexed citations
5.
Oratz, Ruth, et al.. (1990). Antimelanoma monoclonal antibody-ricin A chain immunoconjugate (XMMME-001-RTA) plus cyclophosphamide in the treatment of metastatic malignant melanoma: results of a phase II trial.. PubMed. 9(4). 345–54. 42 indexed citations
6.
S̄pitler, Lynn E., R P Mischak, & Patrick J. Scannon. (1989). Therapy of metastatic malignant melanoma using xomazyme® Mel, a murine monoclonal anti-melanoma ricin A chain immunotoxin. International Journal of Radiation Applications and Instrumentation Part B Nuclear Medicine and Biology. 16(6). 625–627. 8 indexed citations
7.
Harkonen, Scott, Patrick J. Scannon, R P Mischak, et al.. (1988). Phase I study of a murine monoclonal anti-lipid A antibody in bacteremic and nonbacteremic patients. Antimicrobial Agents and Chemotherapy. 32(5). 710–716. 42 indexed citations
8.
Harkonen, Scott, et al.. (1987). Effect of Cyclophosphamide on the Immunogenicity of Monoclonal Antimelanoma Antibody-Ricin A Chain Immunotoxin in Rats. PubMed. 4(3). 151–157. 6 indexed citations
9.
Harkonen, Scott, et al.. (1987). Toxicity and immunogenicity of monoclonal antimelanoma antibody-ricin A chain immunotoxin in rats.. PubMed. 47(5). 1377–82. 32 indexed citations
10.
S̄pitler, Lynn E., Maguy Del Rio, Archie Khentigan, et al.. (1987). Therapy of patients with malignant melanoma using a monoclonal antimelanoma antibody-ricin A chain immunotoxin.. PubMed. 47(6). 1717–23. 167 indexed citations
11.
Mischak, R P & Peter C. Dau. (1981). LYMPHOCYTE BINDING ANTIBODIES AND SUPPRESSOR CELL ACTIVITY IN MYASTHENIA GRAVIS *. Annals of the New York Academy of Sciences. 377(1). 436–446. 8 indexed citations
12.
Mischak, R P, et al.. (1975). Some effects of growth medium composition on the antigenicity of a T-strain mycoplasma. Infection and Immunity. 11(3). 530–539. 16 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Y Fukushi Breakdown of academic impact, for papers by Gretchen N. Schwartz Breakdown of academic impact, for papers by Gerald R. Thrush Breakdown of academic impact, for papers by Sabine Imhof-Jung Breakdown of academic impact, for papers by Raúl A. Ruggiero Breakdown of academic impact, for papers by L Chaplin Breakdown of academic impact, for papers by Birgitta Clinchy Breakdown of academic impact, for papers by Г. И. Дейчман Breakdown of academic impact, for papers by Kazuko Tsuneoka Breakdown of academic impact, for papers by H von Boehmer
Rankless by CCL
2026